|Bid||48.00 x 800|
|Ask||49.57 x 800|
|Day's range||48.33 - 48.80|
|52-week range||36.91 - 58.10|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||17.44|
|Forward dividend & yield||1.75 (3.60%)|
|Ex-dividend date||26 May 2022|
|1y target est||64.00|
Sanofi (NASDAQ: SNY) and AstraZeneca's (NASDAQ: AZN) application for the respiratory syncytial virus (RSV) vaccine candidate called nirsevimab was recently accepted for review by the U.S. Food and Drug Administration (FDA) as a protective option for all infants. Nirsevimab is known by the trade name Beyfortus in the European Union and the United Kingdom, and the FDA expects to make an approval decision on the RSV vaccine in the third quarter of this year.
In the latest trading session, Sanofi (SNY) closed at $48.49, marking a -0.66% move from the previous day.
(Bloomberg) -- Mixed results from Wall Street earlier in January raise the ante on European lenders limbering up to report earnings next week, a week in which the European Central Bank’s Governing Council also meets to set policy for the first time in 2023.Most Read from BloombergAdani Rout Crosses $51 Billion as Stocks Plunge by Daily LimitsPutin Plans New Ukraine Push Despite Losses as He Prepares for Years of WarWe Asked ChatGPT to Make a Market-Beating ETF. Here’s What HappenedHindenburg vs